In the FIGHT trial, patients with locally advanced or metastatic GC with FGFR2b overexpression (with any 2+ or 3+ staining detected by IHC) or FGFR2 amplification (detected by circulating tumor DNA) were included and treated with bemarituzumab in combination with mFOLFOX6 as a first-line therapy, and the survival outcome was compared to the mFOLFOX6 plus placebo group. Here, FGFR2 is linked to neoplasm.